Carregant...
Efficacy and safety of octreotide treatment for diazoxide‐unresponsive congenital hyperinsulinism in China
IMPORTANCE: Octreotide is an off‐label medicine for congenital hyperinsulinism (CHI), but is currently widely used for treatment of patients with CHI. Thus far, variable efficacy and adverse effects have been reported for octreotide. OBJECTIVE: The present study evaluated the efficacy and safety of...
Guardat en:
| Publicat a: | Pediatr Investig |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7331369/ https://ncbi.nlm.nih.gov/pubmed/32851339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ped4.12175 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|